Aims While conventional therapy is curative for most patients with high grade lymphomas,
there is considerable heterogeneity in this diagnosis, with scope to refine treatment …

Altogether knowledge of the genomic landscape of germinal center lymphomas is offering
welcome opportunities in patient risk stratification and therapeutics. The challenge ahead is …

Molecular genetic studies of lymphoma have led to refinements in disease classification in
the most recent World Health Organization update. Nevertheless, a 'one‐size‐fits …

Modern advances in genomics and cancer biology have produced an unprecedented body
of knowledge regarding the molecular pathogenesis of lymphoma. The diverse histological …

The modern taxonomy of disease builds a framework for precision medicine, by which
traditional pathological criteria are integrated with clinical and genomic features to define …

Background: In 2010, we reported that the standard IPI developed in the pre-rituximab era
remains valid also for DLBCL patients (pts) treated with R (ituximab) plus CHOP (Ziepert et …

Lymphomas are a group of hematological malignancies derived from lymphocytes.
Lymphomas are clinically and biologically heterogeneous and have overlapping diagnostic …

The aggressive B-cell lymphomas are a diverse collection of cancers grouped together
based on clinical behavior and derivation from B lymphocytes. Genomic analyses on these …

Molecular diagnostics in low grade B cell lymphoma is currently based on polymerase chain
reaction (PCR) detection of lymphoid clonality or of molecular (onco) genetic markers that …

Lymphomas encompass a diverse group of malignant lymphoid neoplasms. Over recent
years much scientific effort has been undertaken to identify and understand molecular …